Skip to content

Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion

Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05512572
Enrollment
80
Registered
2022-08-23
Start date
2021-08-23
Completion date
2023-08-23
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chalazion

Brief summary

Study method: This test screened the subjects first, and proposed to include 50 subjects with primary or recurrent eyelid plate gland cysts without obvious surgical indications. All subjects underwent three strong pulsed light therapy combined with eyelid plate gland massage, treatment of local anesthesia eye drops, and metal pads were placed in conjunctival sac protection. Eye protection, using the M22 strong pulsed light small optical treatment head of the medical company, energy selection 14-16J/cm2, laser position is selected on the upper and lower eyelids, 3mm away from the root of the eyelashes. Each interval is 3 weeks. Eye-related examinations were performed before treatment and 3 times after treatment. The evaluation content included: ocular surface, slit lamp observation, anterior segment photography, intraocular pressure, vision, corneal fluorescein staining, tear film rupture time, eyelid plate gland evaluation, eyelid plate gland cyst relief, eyelid plate gland cyst recurrence rate.

Interventions

DEVICEIPL

intense pulsed light

PROCEDUREConservative treatment or excision with curettage

conservative treatment or excision with curettage but without IPL-MGX treatment as a control

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients had primary or recurrent eyelid plate gland cyst without obvious surgical indications

Exclusion criteria

* (1) any intraocular inflammation, ocular infection, allergy, ocular surgery, or ocular trauma in the past 6 months; (2) any eyelid diseases or structural abnormality; (3) any systematic diseases may lead to dry eye or MGD; (4) skin cancer or pigmented lesion in the treatment zone.

Design outcomes

Primary

MeasureTime frameDescription
Recurrence rate of chalaziaAn average of 1 yearThe recurrence of the chalazia

Countries

China

Contacts

Primary Contactming xiu jin
mailto:18344980413@qq.com13989455778
Backup Contactrui yi zhu
mailto:zhuyirui001@126.com15868805518

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026